

## Lucid Diagnostics Sustainability Accounting Standards Board Index

Lucid Diagnostics is proud to present 2021 annual Sustainability Accounting Standards Board (SASB) index with focus on Medical Equipment and Supplies. We recognize providing transparent financial input and relevant company responsibility towards sustainability is critical to investors and stakeholders. We seek to continue to drive meaningful difference towards sustainability and social needs while driving business value. Data provided in this report is reflected from the calendar year of 2021, unless stated otherwise.

TOPIC	CODE	SASB Metric	2021 Reporting
Affordability and Pricing	SASB HC-MS-240a.2	Description of how price information for each product is disclosed to customers or to their agents	Price Information Disclosure: The boundaries of our pricing guidelines for our medical technologies are largely governed by third-party health insurance carriers and must fit within those boundaries to be economically viable for clinical providers and therefore affordable for patient access. Consequently, price information disclosure is very transparent because of health care insurance economic influence on customer decisions.

TOPIC	CODE	SASB Metric	2021 Reporting
Affordability and Pricing	SASB HC-MS-240a.1	Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index	<p>Price Increases: 0</p> <p>Please refer to our annual report on <a href="#">Form 10-K</a> as filed with the SEC noting relevant disclosures regarding contractual agreements with manufacturers and customers and certain risk factors that may impact product pricing. Furthermore, our marketing strategies are governed by honesty and transparency, consistent with our Company values and <a href="#">Code of Ethics</a>. Additionally, the boundaries of our pricing guidelines for our medical technologies are largely governed by third-party health insurance carriers and must fit within those boundaries to be economically viable for clinical providers and therefore affordable for patient access.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Business Ethics	SASB HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	<p>Monetary Losses as a Result of Legal Proceedings: 0</p> <p>There have been no corporate monetary losses as a result of any domestic or foreign corrupt practices ever in the history of the Company. The Company has a robust COSO framework as provided for in compliance with the Sarbanes Oxley Act (Sox control environment). Furthermore, the company uses an outside party (BDO accountants) to test the reliability of and the compliance with the comprehensive system of internal controls and annually issues a report to the Company's audit committee detailing the testing results and whether there are any deficiencies noted in the design of the controls or whether the controls designed were not operating effectively. Additionally, the Sox controls includes a robust set of controls specifically designed to assure that any fraud, errors, or irregularities will not go undetected. BDO's testing of those controls includes not only the detail inspection of documents but also includes interviews with key leadership and directors where the risk of potential fraud could exist.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Business Ethics	SASB HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	<p>Health Care Professionals Code of Ethics: Lucid Diagnostics has a Corporate Travel policy that references the Sunshine Act. The policy describes how and when to utilize the Health Care Professional (HCP) section for reporting payments.</p> <p>The <a href="#">Code of Ethics</a> and the Employee Handbook provides further guidance on expected behavior by all employees.</p> <p>In addition, PAVmed (Lucid Diagnostics' parent company) is a signatory on the <a href="#">AdvaMed Code of Ethics</a> to ensure collaborative relationships between the company and health care professionals meet the highest ethical standards with guidance based on six cornerstone values: innovation, education, integrity, respect, responsibility, and transparency.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Ethical Marketing	SASB HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	<p>Off-label Use Code of Ethics:</p> <p>Our Corporate <a href="#">Code of Ethics</a> is published on our website and all employees, directors, customers, and vendor relationships are expected to abide it. It is reflected in every behavior pattern we promote, particularly how the outside world views us thru our ethical marketing efforts. The policy is intended to promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships and promote compliance with applicable governmental laws, rules, and regulations. The code specifically demands a duty to the Company to act with integrity and to be fair, honest, and candid. It requires all of us to refrain from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts (example encouragement of "Off-Label" use of our products), or any other unfair-dealing practice. These principles, among other Conduct expectations are fully delineated further in our published Code of Ethics and in our Employee Handbook that each employee acknowledges receipt upon commencement of employment.</p> <p>In addition, PAVmed (Lucid Diagnostics' parent company) is a signatory on the <a href="#">AdvaMed Code of Ethics</a> to ensure collaborative relationships between the company and health care professionals meet the highest ethical standards with guidance based on six cornerstone values: innovation, education, integrity, respect, responsibility, and transparency.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Ethical Marketing	SASB HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	<p>Amount of Monetary Losses: 0</p> <p>For FY 2021, Lucid Diagnostics had no monetary losses due to legal proceedings due to false marketing claims or monetary liabilities to others.</p>
Product Design & Lifecycle Management	SASB HC-MS-410a.2	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	<p>Number of Products Accepted for Takeback and Reused, Recycled, or Donated: 0</p> <p>Zero products and supplies have been accepted for takeback. Continual efforts are made to evaluate longer useful life of product performance.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
<p><b>Product Design &amp; Lifecycle Management</b></p>	<p>SASB HC-MS-410a.1</p>	<p>Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products</p>	<p>Process to Assess and Manage Environmental and Human Health: Lucid Diagnostics regularly assesses its processes to review opportunities to minimize negative environmental and human health impacts. Our current practices focus on material, supply chain, and animal welfare processes. Lucid Diagnostics carefully selects non-toxic materials for its products and monitors opportunities to minimize product waste. All products are tested for biocompatibility including toxicology testing to ensure all materials are safe for the intended human use and minimize environmental harm. In addition, this year Lucid Diagnostics has started evaluating removal of unnecessary packing materials, like shelf boxes, and will integrate this practice into its devices where possible. We have also begun exploration of removing paper IFUs from our packaging in favor of eIFUs where regulation allows. In addition to material usage monitoring, Lucid Diagnostics continually evaluates other opportunities for efficiency including alternative sterilization options that minimize supply chain logistics and additional processing associated with environmental impact. Finally, Lucid Diagnostics minimizes animal testing where possible by exploring alternative bench test models and designing tests to minimize the number of animals required. When animal testing is required, Lucid Diagnostics ensures the standard of care of animal welfare is achieved by utilizing Institutional Animal Care and Use Committees (IACUCs) that adhere to the Animal Welfare Act of the U.S. Public Health Service and The NIH Office of Laboratory Animal Welfare (OLAW) policies. Ongoing efforts will be made to assess additional opportunities to track and minimize environmental and human health impacts.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Product Safety	SASB HC-MS-250a.1	Number of recalls issued, total units recalled	<p>Number of Recalls: 0</p> <p>For FY 2021, there have been no voluntary and/or mandated recalls for product distributed by Lucid Diagnostics.</p>
Product Safety	SASB HC-MS-250a.4	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	<p>Number of FDA Enforcement Actions Taken: 0</p> <p>For FY 2021, there have been no enforcement actions taken by the FDA.</p>
Product Safety	SASB HC-MS-250a.2	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	<p>Products Listed in the FDA's MedWatch Safety Alerts: None.</p> <p>For FY 2021, there have been no reported product listed in <a href="#">MedWatch Safety Alerts</a> for Human Medical Products under Lucid Diagnostics. We report all necessary data as required by FDA.</p>
Product Safety	SASB HC-MS-250a.3	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience	<p>Number of Fatalities Related to Products: 0</p> <p>For FY 2021, there have been no reported fatalities as a result of using product by Lucid Diagnostics. We report all necessary data as required by FDA.</p>

TOPIC	CODE	SASB Metric	2021 Reporting
Supply Chain Management	SASB HC-MS-430a.3	Description of the management of risks associated with the use of critical materials	Critical Material Risk Management: Lucid Diagnostics is evaluating suppliers and their capability of maintaining supplies and inventory to minimize risk to supply chain. In addition, Lucid Diagnostics continues to seek new suppliers for dual sourcing while maintaining strong relationship with existing suppliers. This is by means of upfront forecast/demand planning and frequent communication.
Supply Chain Management	SASB HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain	Efforts to Maintain Traceability: Lucid Diagnostics requires traceability from the component level to finished good manufacturing. This is required from component supplier, contract manufacturer, service provider (such as sterilization), and distribution centers. This is required per Lucid Diagnostics' quality system and respective quality agreements. Finished goods inventory and lot management utilizes barcode technology.
Supply Chain Management	SASB HC-MS-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers facilities participating in third-party audit programs for manufacturing and product quality	<p>Percentage of facilities and tier I suppliers facilities participating in third-party audits: 100</p> <p>For FY2021, Lucid Diagnostics did not have an internal manufacturing facility, therefore information on third party audit at internal facility is not available at this time. All suppliers are assessed by criticality level. Tier 1 suppliers used by Lucid Diagnostics are considered Level 1 (critical) suppliers. All suppliers at Level 1 (critical) requires ISO certification and/or industry specific accreditations. Suppliers at Level 2 and 3 are assessed per our quality system requirements.</p>